Neurona Therapeutics

Our CEO, Cory R. Nicholas, PhD, was recently featured in a blog by the California Institute for Regenerative Medicine, in which he provided an update on the clinical development of NRTX-1001, our off-the-shelf neural cell therapy designed to treat drug-resistant focal epilepsy. The discussion highlighted the recent U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for NRTX-1001, as well as the novel cell therapy's potential to treat epilepsy and other degenerative diseases like Alzheimer’s disease, and the implications for patients and the future of regenerative medicine. We are deeply grateful for CIRM’s ongoing support, which has been vital to our progress. Neurona remains committed to the vision of regenerative cell therapy that CIRM has championed.

We are thrilled to welcome Nadia Agopyan, Ph.D., RAC, to the Neurona team as our Senior Vice President of Regulatory Affairs. Nadia brings over 20 years of experience in leading global regulatory strategy for drugs and biologics, including cell therapies. Her expertise will be invaluable as we advance our regenerative neural cell therapies through clinical development. Welcome, Nadia! We look forward to achieving great milestones together in our mission to develop life-changing therapies for neurological disorders! Learn more here: https://lnkd.in/gRh75K5B

Today Neurona announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the company’s lead product candidate, NRTX-1001, which is being developed for drug-resistant mesial temporal lobe epilepsy (MTLE). The RMAT program is dedicated to advancing investigational regenerative medicines, including cell therapies, that are intended to treat, modify, reverse, or cure serious diseases where preliminary clinical evidence indicates that the regenerative medicine therapy has the potential to address unmet medical needs. Learn more about NRTX-1001 and this development in the press release here: https://lnkd.in/eJHzyZ6P #epilepsy #celltherapy

Director of Discovery Research at Neurona, Marina Bershteyn, Ph.D., has been invited to present a seminar titled "Development of allogeneic GABAergic inhibitory interneuron cell therapy for drug-resistant focal epilepsy" at the Cell Based Therapeutics of Brain Diseases Meeting, which is part of the Neuroscience School of Advanced Studies Challenge Workshops. Marina's presentation will outline recent clinical data and supporting preclinical data from Neurona's ongoing clinical trial of NRTX-1001 which is demonstrating the potential to significantly reduce seizure frequency in adults with unilateral mesial temporal lobe epilepsy (MTLE).  Learn more about NRTX-1001 and our clinical trials here: https://lnkd.in/e37V9uf2 Learn more about the meeting here: https://lnkd.in/eVRp7Wbx

We are delighted to announce that Manher (AJ) Joshi, M.D., has joined Neurona as Chief Medical Officer. AJ brings a wealth of clinical development and commercialization expertise across a variety of neuro-focused indications and has extensive experience in the development of cell therapies. We look forward to his leadership as we advance our pipeline of cellular therapeutic candidates for neurological diseases, including NRTX-1001 for drug-resistant focal epilepsy. Welcome to the Neurona team, AJ! Learn more about AJ's background here: https://lnkd.in/eMjD7Tvs #epilepsy #celltherapy

If you are attending the Jefferies Global Healthcare Conference in New York City this week, our CEO, Cory R. Nicholas, PhD, will be hosting meetings to update investors on the most recent data from Neurona's ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-resistant, unilateral mesial temporal lobe epilepsy (MTLE) and the Company's plans to develop its pipeline of allogeneic, off-the-shelf, regenerative neural cell therapy products. #epilepsy #celltherapy

If you are attending #ASGCT2024 please stop by Poster # 842 on Wednesday, May 8th when Neurona team member Brianna Feld will be presenting supporting preclinical data and the most recent clinical update from our hpsc-derived inhibitory interneuron cell therapy, NRTX-1001, which is being evaluated in an ongoing clinical trial in adults with drug-resistant focal #epilepsy. 

At the Annual Meeting of the American Academy of Neurology ,#AAN2024, today, our CEO, Cory R. Nicholas, PhD, is presenting a clinical update on the first cohort of our ongoing Phase I/II clinical trial of NRTX-1001, which is being evaluated in people with drug-resistant focal #epilepsy. Read the details in our press release here: https://lnkd.in/e4yuHJiK

Looking forward to the upcoming discussion between Elias Uhlin and our cofounder and CEO, Cory R. Nicholas, PhD, as part of the ATMP World Tour, on the development and early clinical data from the ongoing Phase 1/2 clinical trial of NRTX-1001, a novel, regenerative cell therapy which is being evaluated for the treatment of mesial temporal lobe #epilepsy (MTLE). Learn more about the ATMP World Tour and how to listen to this session here: https://lnkd.in/ggS_UR6V

On Tuesday, March 26th, Neurona employees celebrated #PurpleDay, an international initiative dedicated to increasing awareness about #epilepsy. John Hixson, MD, Neurona's senior medical director, and a neurologist and practicing epilepsy specialist, gave a fascinating presentation explaining the range of conditions experienced by his patients, the standard interventions that are currently available to them, and the work being done by Neurona to develop NRTX-1001, a regenerative cell therapy that is currently being studied as a potentially safe and effective therapeutic option for people with drug-resistant focal epilepsy.